Table 1.
Donor, patient, disease and transplant characteristics
| Characteristics | Number (%) |
|---|---|
| Donor age, y | |
| 10-29 | 279 (30) |
| 30-49 | 420 (45) |
| 50-80 | 229 (25) |
| Donor-recipient relationship | |
| Parent | 120 (13) |
| Sibling | 358 (39) |
| Offspring | 450 (48) |
| Donor-recipient sex match | |
| Male donor/male recipient | 335 (36) |
| Male donor/female recipient | 208 (23) |
| Female donor/male recipient | 224 (24) |
| Female donor/female recipient | 161 (17) |
| Donor-recipient ABO match | |
| Matched | 530 (57) |
| Major mismatch | 147 (16) |
| Minor mismatch | 114 (12) |
| Not reported | 137 (15) |
| Donor-recipient cytomegalovirus serostatus match | |
| Donor negative/recipient negative | 232 (25) |
| Donor negative/recipient positive | 234 (25) |
| Donor positive/recipient negative | 119 (13) |
| Donor positive/recipient positive | 335 (36) |
| Not reported | 8 (1) |
| Donor sex and parity | |
| Male | 543 (59) |
| Female, nulliparous | 95 (10) |
| Female, parous | 223 (24) |
| Female, parity not reported | 57 (6) |
| Sex, not reported | 10 (< 1) |
| Patient age, y | |
| 18-54 | 480 (52) |
| 55-78 | 448 (48) |
| Recipient race | |
| White | 658 (71) |
| African American | 197 (21) |
| Other | 73 (8) |
| Performance score | |
| 90-100 | 572 (62) |
| <90 | 308 (33) |
| Not reported | 48 (5) |
| Hematopoietic cell transplant-comorbidity index | |
| 0-2 | 587 (63) |
| ≥3 | 341 (37) |
| Disease | |
| Acute myeloid leukemia | 415 (45) |
| Acute lymphoblastic leukemia | 136 (15) |
| Myelodysplastic syndrome | 117 (13) |
| Non-Hodgkin lymphoma | 199 (21) |
| Hodgkin lymphoma | 61 (6) |
| Disease risk index | |
| Low risk | 85 (9) |
| Intermediate risk | 573 (62) |
| High risk | 270 (29) |
| Graft type* | |
| Bone marrow | 632 (68) |
| Peripheral blood | 296 (32) |
| Conditioning regimen | |
| Myeloablative | |
| Total body irradiation + fludarabine | 80 (9) |
| Total body irradiation + other agents | 49 (5) |
| Busulfan + cyclophosphamide | 123 (13) |
| Busulfan + fludarabine | 28 (3) |
| Reduced intensity | |
| Total body irradiation + cyclophosphamide + fludarabine | 549 (59) |
| Total body irradiation + other agents | 29 (3) |
| Melphalan + fludarabine | 70 (8) |
| Transplant period | |
| 2008-2011 | 277 (30) |
| 2012-2015 | 651 (70) |
*
The median total nucleated cell dose for bone marrow grafts was 3 × 108/kg; interquartile range, 2 to 4 × 108/kg. The median CD34 dose of peripheral blood grafts was 6 × 106/kg; interquartile range, 5 to 9 × 106/kg.